

ASX ANNOUNCEMENT

CELLMID CAPITAL RAISING

**SYDNEY, Tuesday, 1 November 2016: Cellmid Limited** (ASX: CDY) (the **Company**), is pleased to advise that it received commitments totalling \$3 million, for new fully paid shares in the Company at 3 cents per Placement Share (the **Placement**). The Placement was supported by new institutional and sophisticated investors as well as existing shareholders.

The Company will use the funds raised to launch the evolis® FGF5 inhibitor hair growth products in the US market.

In July 2016 Cellmid's wholly owned subsidiary, Advangen Limited, signed a distribution partnership with Colour Collective, a Dallas based group specialising in hair product launches in the US. The partnership provides access to a number of distribution channels, facilities and marketing experts for the launch of the evolis® products.

Together with the \$1.2 million raised through the exercise of options in October 2016, the Placement will allow the company to invest into the launch of the evolis® products in the USA, including product manufacture, digital and social media, salons and high end retail distribution.

**Details of the Placement**

Under the Placement, binding commitments have been received to subscribe for 100 million Placement Shares at a price of 3 cents per Placement Share, representing \$3 million.

The issue price for the Placement Shares represents a 14% discount to the last closing price of the Company's shares prior to the placement on Tuesday, 25 October 2016.

The Placement was available to investors in Australia who qualified as professional or sophisticated investors under the requirements of the Corporations Act 2001 (Cth) and sophisticated and professional investors in select other jurisdictions.

The Placement Shares are expected to be issued between Wednesday 3 November 2016 and Monday, 7 November 2016. The Placement Shares will rank equally in all respects with existing ordinary shares from the issue date of allotment. The Placement Shares will be issued in accordance with LR7.1 and will not require shareholders' approval.

End

Contact:

Maria Halasz, CEO

T +612 9221 6830

 @mariahalasz

For personal use only

### **Cellmid Limited (ASX: CDY)**

Cellmid is an Australian life sciences company with lead programs in multiple disease indications. The Company, through its wholly owned subsidiaries, Lyramid, Kinera and Advangen, develops and markets innovative novel therapies and diagnostic tests for fibrotic diseases, cancer, ischemic diseases of the heart and hair loss. Cellmid holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) and FGF5 globally. Intellectual property pertaining to midkine is being exploited through wholly owned subsidiaries Lyramid and Kinera. Advangen, Cellmid's consumer health business, sells its FGF5 inhibitor hair growth products in Australia and Japan, and currently expanding distribution in other territories. For further information, please see [www.cellmid.com.au](http://www.cellmid.com.au) and [www.evolisproducts.com.au](http://www.evolisproducts.com.au).

### **Advangen Limited and hair growth products**

Advangen Limited is Cellmid's wholly owned subsidiary engaged in the development and sale of anti-aging hair care products. Advangen has a range of FGF5 inhibitor hair growth products which are sold in Australia and Japan with a USA launch currently ongoing. Advangen has a rich portfolio of hair growth and anti-aging hair care assets which include formulations of products on market, trademarks, patents and patent applications, proprietary assays and manufacturing processes.

### **Midkine (MK)**

Midkine is a growth factor that is highly expressed during embryonic development. Midkine modulates many important biological interactions such as cell growth, cell migration and cellular adherence. These functions are relevant to cancer, inflammation, autoimmunity, ischemia, nerve growth/repair and wound healing. Midkine is barely detectable in healthy adults and only occurs as a consequence of the pathogenesis of a number of different disorders. Midkine expression is often evident very early in disease onset, even before any apparent physical symptoms. Accordingly, midkine is an important early marker for diagnosing cancers and autoimmune diseases. Finally, midkine is only evident in a disease context, and targeting midkine is not expected to harm normal healthy tissues.

### **Investment in life sciences companies**

There are a number of inherent risks associated with the research, development and commercialisation of pharmaceutical products. Investment in companies specialising in these activities carry specific risks which are different to those associated with trading and manufacturing businesses. As such, these companies should be regarded as highly speculative. Cellmid recommends that investors seek professional advice before making an investment in its shares.

For personal use only